Array BioPharma
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is a subsidiary of Pfizer.
| Type | Subsidiary of Pfizer |
|---|---|
| Industry | Oncology Medication |
| Founded | 1998 |
| Founder | Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou |
| Headquarters | , |
| Revenue | $173.8 million (2018) |
| Parent | Pfizer |
| Website | www |
History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]
In November 2000, the company became a public company via an initial public offering.[2]
In June 2019, Pfizer acquired the company for approximately $11 billion.[3]
References
- "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
- "Array IPO up 17%". CNN. November 17, 2000.
- "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.